Category: Featured

Newsroom_images_noText_R3_2

Theranos, Arizona Attorney General Reach Agreement on Full Restitution to State Consumers

Company to reimburse more than those whose tests were voided and corrected; Resolution ends all existing and potential claims against Theranos in the state.

April 18, 2017
Newsroom_images_noText_R3_

Theranos Reaches Resolution with Centers For Medicare & Medicaid Services

CMS withdraws revocation of CLIA certificates and reduces civil monetary penalty; Theranos withdraws appeal, completing exit from the clinical lab business.

April 17, 2017
Newsroom_images_noText_R3_2

Theranos Announces Engineering Experts Join Company’s New Technology Advisory Board

Theranos, Inc. announced that engineering and biomedical device design experts have joined the company’s newly created Technology Advisory Board (TAB).

January 17, 2017
Newsroom_images_noText_R3_

Company Re-engineers Operations

Theranos announces further re-engineering of the company’s operations.

January 6, 2017
Newsroom_images_noText_R3_2

Theranos Enhances Executive Ranks

Theranos names operations chief, communications leader, general counsel to executive team; adds molecular pathologist to scientific board.

December 12, 2016
Newsroom_images_noText_R3_

Theranos Adds Silicon Valley Executive to Board of Directors

Riley Bechtel Retires from Board; Company to Retire Board of Counselors Structure in Consolidation of Advisory Framework

December 1, 2016
Newsroom_images_noText_R3_2

Theranos Statement on Walgreens Suit

Theranos responds to reports of Walgreens suit against the company.

November 8, 2016
Newsroom_images_noText_R3_

COMPANY STATEMENT REGARDING INVESTOR LAWSUIT

Theranos responds to recent report of a lawsuit filed by an investor.

October 11, 2016
Newsroom_images_noText_R3_2

An Open Letter From Elizabeth Holmes

Read CEO Elizabeth Holmes' letter announcing new company focus at Theranos.

October 5, 2016
Newsroom_images_noText_R3_

Theranos to Appeal CMS Sanctions

Theranos has filed a notice of intent to appeal the sanctions that the Centers for Medicare and Medicaid Services (CMS) imposed last month on the company’s Newark, California lab.

August 25, 2016